Cheng, Lesley
Quek, Camelia
Li, Xia
Bellingham, Shayne A.
Ellett, Laura J.
Shambrook, Mitch
Zafar, Saima
Zerr, Inga
Lawson, Victoria A.
Hill, Andrew F. http://orcid.org/0000-0001-5581-2354
Funding for this research was provided by:
Department of Health | National Health and Medical Research Council (1132604)
Article History
Received: 27 May 2020
Accepted: 19 February 2021
First Online: 25 March 2021
Competing interests
: All the authors declare no conflicts of interest apart from L.C. and A.F.H. L.C. and A.F.H. report grants from the National Health and Medical Research Council of Australia, grants from the Australian Creutzfeldt-Jakob Disease Support Group Network, during the conduct of the study; In addition, L.C. and A.F.H. have patented novel methods for dementia diagnosis (Provisional patent #: 2018904605) pending. A.F.H. is a shareholder in D-Gen Ltd which markets the ICSM18 antibody used in this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
: All serum samples were collected by the Clinical Dementia Centre Göttingen. All patients provided written informed consent or their legal next of kin and approved from the local Ethics committee of the University Hospital of Göttingen as previously published<sup>17</sup>.